Emocromatosi ereditaria: Dalla genetica alla clinica

Translated title of the contribution: Inherited hemochromatosis: From genetics to clinics

C. Camaschella, R. Merlini

Research output: Contribution to journalArticle

Abstract

Hereditary hemochromatosis is one of the most common autosomal recessive disorder among Caucasians since the genotype at risk for hemochromatosis accounts for 1:200-400 individuals of Northern European ancestry. The disease is characterized by an inappropriately increased intestinal iron absorption leading to early abnormalities of iron parameters followed by iron deposition in different organs. Excessive iron causes tissue damage and fibrosis, leading to organ failure. Clinical complications appear late in life and include liver cirrhosis, diabetes, cardiomyopathy, hypogonadism, arthropathy, skin pigmentation and susceptibility to liver cancer. Clinical symptoms develop only in homozygotes. Heterozy-gotes may show abnormalities of iron parameters, but are not clinically affected, unless carriers of other conditions which modify iron metabolism, such as chronic liver diseases, beta-thalassemia trait or other haemolytic anemias. The phenotypic expression of the disease is variable even within the same family, due to the effect of modifier genes or to environmental factors. Recent progress of genetics and molecular biology have shown that hemochromatosis is an heterogeneous disease, that may result from the inactivation of different genes. The identification of mutations of HFE and of other genes involved in the disease has allowed to develop molecular tests to support early diagnosis, allowing also to ameliorate the differential diagnosis with other iron loading disorders. In addition, the increased knowledge acquired from the study of hemochromatosis has contributed to clarify the pathophysiology of iron metabolism. For this reason hemochromatosis is considered a typical example of molecular medicine.

Original languageItalian
Pages (from-to)207-222
Number of pages16
JournalMinerva Medica
Volume96
Issue number3
Publication statusPublished - Jun 2005

Fingerprint

Hemochromatosis
Iron
Modifier Genes
Molecular Medicine
Skin Pigmentation
Hypogonadism
Joint Diseases
beta-Thalassemia
Hemolytic Anemia
Intestinal Absorption
Homozygote
Gene Silencing
Liver Neoplasms
Cardiomyopathies
Liver Cirrhosis
Liver Diseases
Molecular Biology
Early Diagnosis
Differential Diagnosis
Fibrosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Emocromatosi ereditaria : Dalla genetica alla clinica. / Camaschella, C.; Merlini, R.

In: Minerva Medica, Vol. 96, No. 3, 06.2005, p. 207-222.

Research output: Contribution to journalArticle

Camaschella, C & Merlini, R 2005, 'Emocromatosi ereditaria: Dalla genetica alla clinica', Minerva Medica, vol. 96, no. 3, pp. 207-222.
Camaschella, C. ; Merlini, R. / Emocromatosi ereditaria : Dalla genetica alla clinica. In: Minerva Medica. 2005 ; Vol. 96, No. 3. pp. 207-222.
@article{4a0b38437f3641a7bde4e38fc2d61c1f,
title = "Emocromatosi ereditaria: Dalla genetica alla clinica",
abstract = "Hereditary hemochromatosis is one of the most common autosomal recessive disorder among Caucasians since the genotype at risk for hemochromatosis accounts for 1:200-400 individuals of Northern European ancestry. The disease is characterized by an inappropriately increased intestinal iron absorption leading to early abnormalities of iron parameters followed by iron deposition in different organs. Excessive iron causes tissue damage and fibrosis, leading to organ failure. Clinical complications appear late in life and include liver cirrhosis, diabetes, cardiomyopathy, hypogonadism, arthropathy, skin pigmentation and susceptibility to liver cancer. Clinical symptoms develop only in homozygotes. Heterozy-gotes may show abnormalities of iron parameters, but are not clinically affected, unless carriers of other conditions which modify iron metabolism, such as chronic liver diseases, beta-thalassemia trait or other haemolytic anemias. The phenotypic expression of the disease is variable even within the same family, due to the effect of modifier genes or to environmental factors. Recent progress of genetics and molecular biology have shown that hemochromatosis is an heterogeneous disease, that may result from the inactivation of different genes. The identification of mutations of HFE and of other genes involved in the disease has allowed to develop molecular tests to support early diagnosis, allowing also to ameliorate the differential diagnosis with other iron loading disorders. In addition, the increased knowledge acquired from the study of hemochromatosis has contributed to clarify the pathophysiology of iron metabolism. For this reason hemochromatosis is considered a typical example of molecular medicine.",
keywords = "Hemocromatosis, diagnosis, Hemocromatosis, genetics, Hemocromatosis, therapy",
author = "C. Camaschella and R. Merlini",
year = "2005",
month = "6",
language = "Italian",
volume = "96",
pages = "207--222",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Emocromatosi ereditaria

T2 - Dalla genetica alla clinica

AU - Camaschella, C.

AU - Merlini, R.

PY - 2005/6

Y1 - 2005/6

N2 - Hereditary hemochromatosis is one of the most common autosomal recessive disorder among Caucasians since the genotype at risk for hemochromatosis accounts for 1:200-400 individuals of Northern European ancestry. The disease is characterized by an inappropriately increased intestinal iron absorption leading to early abnormalities of iron parameters followed by iron deposition in different organs. Excessive iron causes tissue damage and fibrosis, leading to organ failure. Clinical complications appear late in life and include liver cirrhosis, diabetes, cardiomyopathy, hypogonadism, arthropathy, skin pigmentation and susceptibility to liver cancer. Clinical symptoms develop only in homozygotes. Heterozy-gotes may show abnormalities of iron parameters, but are not clinically affected, unless carriers of other conditions which modify iron metabolism, such as chronic liver diseases, beta-thalassemia trait or other haemolytic anemias. The phenotypic expression of the disease is variable even within the same family, due to the effect of modifier genes or to environmental factors. Recent progress of genetics and molecular biology have shown that hemochromatosis is an heterogeneous disease, that may result from the inactivation of different genes. The identification of mutations of HFE and of other genes involved in the disease has allowed to develop molecular tests to support early diagnosis, allowing also to ameliorate the differential diagnosis with other iron loading disorders. In addition, the increased knowledge acquired from the study of hemochromatosis has contributed to clarify the pathophysiology of iron metabolism. For this reason hemochromatosis is considered a typical example of molecular medicine.

AB - Hereditary hemochromatosis is one of the most common autosomal recessive disorder among Caucasians since the genotype at risk for hemochromatosis accounts for 1:200-400 individuals of Northern European ancestry. The disease is characterized by an inappropriately increased intestinal iron absorption leading to early abnormalities of iron parameters followed by iron deposition in different organs. Excessive iron causes tissue damage and fibrosis, leading to organ failure. Clinical complications appear late in life and include liver cirrhosis, diabetes, cardiomyopathy, hypogonadism, arthropathy, skin pigmentation and susceptibility to liver cancer. Clinical symptoms develop only in homozygotes. Heterozy-gotes may show abnormalities of iron parameters, but are not clinically affected, unless carriers of other conditions which modify iron metabolism, such as chronic liver diseases, beta-thalassemia trait or other haemolytic anemias. The phenotypic expression of the disease is variable even within the same family, due to the effect of modifier genes or to environmental factors. Recent progress of genetics and molecular biology have shown that hemochromatosis is an heterogeneous disease, that may result from the inactivation of different genes. The identification of mutations of HFE and of other genes involved in the disease has allowed to develop molecular tests to support early diagnosis, allowing also to ameliorate the differential diagnosis with other iron loading disorders. In addition, the increased knowledge acquired from the study of hemochromatosis has contributed to clarify the pathophysiology of iron metabolism. For this reason hemochromatosis is considered a typical example of molecular medicine.

KW - Hemocromatosis, diagnosis

KW - Hemocromatosis, genetics

KW - Hemocromatosis, therapy

UR - http://www.scopus.com/inward/record.url?scp=27844497909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844497909&partnerID=8YFLogxK

M3 - Articolo

C2 - 16175162

AN - SCOPUS:27844497909

VL - 96

SP - 207

EP - 222

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 3

ER -